Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay

被引:10
作者
Bosanquet, AG [1 ]
Copplestone, JA
Johnson, SAN
Smith, AG
Povey, SJ
Orchard, JA
Oscier, DG
机构
[1] Royal United Hosp, Canc Res Unit, Bath BA1 3NG, Avon, England
[2] Derriford Hosp, Plymouth PL6 8DH, Devon, England
[3] Taunton & Somerset Hosp, Taunton, Somerset, England
[4] Royal S Hants Hosp, Southampton SO9 4PE, Hants, England
[5] Janssen Cilag Ltd, Saunderton, Bucks, England
[6] Royal Bournemouth Hosp, Bournemouth, Dorset, England
关键词
cladribine; differential staining cytotoxicity assay; phase II trial;
D O I
10.1046/j.1365-2141.1999.01581.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The ability to identify non-responders to cytotoxic chemotherapy has significant clinical and economic benefits. Differential staining cytotoxicity (DiSC) assays were performed in 34 previously treated patients with chronic lymphocytic leukaemia prior to treatment with cladribine. Of the 28 identified as ex vivo sensitive, 26 achieved a complete (CR) or partial response (PR) (median length of response 1.5 years, median survival 3.37 years) and two had a >70% fall in lymphocytes: six identified as ex vivo resistant failed to respond. The DiSC assay can accurately identify a subgroup of patients resistant to cladribine.
引用
收藏
页码:474 / 476
页数:3
相关论文
共 13 条
  • [1] CORRELATIONS BETWEEN THERAPEUTIC RESPONSE OF LEUKEMIAS AND INVITRO DRUG-SENSITIVITY ASSAY
    BOSANQUET, AG
    [J]. LANCET, 1991, 337 (8743) : 711 - 714
  • [2] Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined disc assay methodology
    Bosanquet, AG
    Bell, PB
    [J]. LEUKEMIA RESEARCH, 1996, 20 (02) : 143 - &
  • [3] Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay
    Bosanquet, AG
    Johnson, SA
    Richards, SM
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (01) : 71 - 77
  • [4] In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues -: correlation with clinical course
    Bromidge, TJ
    Turner, DL
    Howe, DJ
    Johnson, SA
    Rule, SAJ
    [J]. LEUKEMIA, 1998, 12 (08) : 1230 - 1235
  • [5] Autoimmune haemolysis in patients with B-CLL treated with chlorodeoxyadenosine (CDA)
    Chasty, RC
    Myint, H
    Oscier, DG
    Orchard, JA
    Bussutil, DP
    Hamon, MD
    Prentice, AG
    Copplestone, JA
    [J]. LEUKEMIA & LYMPHOMA, 1998, 29 (3-4) : 391 - 398
  • [6] National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
    Cheson, BD
    Bennett, JM
    Grever, M
    Kay, N
    Keating, MJ
    OBrien, S
    Rai, KR
    [J]. BLOOD, 1996, 87 (12) : 4990 - 4997
  • [7] DELANNOY A, 1995, LEUKEMIA, V9, P1130
  • [8] INVITRO CHEMOSENSITIVITY TESTING IN CHRONIC LYMPHOCYTIC-LEUKEMIA PATIENTS
    HANSON, JA
    BENTLEY, DP
    BEAN, EA
    NUTE, SR
    MOORE, JL
    [J]. LEUKEMIA RESEARCH, 1991, 15 (07) : 565 - 569
  • [9] Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia
    Juliusson, G
    Christiansen, I
    Hansen, MM
    Johnson, S
    Kimby, E
    ElmhornRosenborg, A
    Liliemark, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) : 2160 - 2166
  • [10] LAMBERT E, 1992, LEUKEMIA, V6, P1063